Fluibron® Aerosol and Syrup: Price, Indications and Dosage
Fluibron® is a medicine produced and distributed in Italy by the pharmaceutical company Chiesi Farmaceutici SpA which owes its action to ambroxol, an active principle which serves to make the mucus more fluid.
It is recommended for cases of respiratory tract diseases with the presence of mucus. The drug works by making the mucus thinner and consequently easier to dispose of. Fluibron® is administered to those patient
How much?
On the market in our country we can find the following pharmaceutical forms of Fluibron®:
- Fluibron Syrup®, 15 mg/5 ml, syrup, 200 mL bottle;
- Fluibron tablets® 30 mg in packs of 30 tablets;
- Granular Fluibron® 30 mg sachets in packs of 30 sachets;
- Fluibron Aerosol® 15 mg 2 mL vials in packs of 20 vials;
- Fluibron® suspension to be nebulised 0.75% bottle 40 mL bottle.
How does it work?
Fluibron® is a medicine that belongs to the category of mucolytic drugs, which work by making the mucus easier to eliminate by thinning it, the drug is used in those patients who suffer from acute diseases affecting the respiratory tract with thick and viscous mucus.
s who have acute respiratory tract disease problems with thick and viscous mucus.
Fluibron® owes its action to ambroxol. This active ingredient regulates the transport of mucus secretions in the respiratory tract, has a mucolytic and also mucoregulatory activity. It has its effect on the quality of the mucus, on the alveolar surfactant production and finally on the ciliary function.
How is it assumed?
The drug in tablets should be taken, in adults, with 1 tablet 3 times a day and for maintenance 1 tablet 2 times a day. The granules for oral suspension should be taken in adults at a dosage of 1 sachet 3 times a day while the maintenance dose is 1 sachet 2 times a day. Tablets and granules should be taken after meals and with a little water.
The syrup should be taken at a dosage of 10 mL of syrup 3 times a day, for maintenance 5 mL 3 times a day. For children, use Fluibron® syrup or sachets for children. The syrup in children from 2 to 5 years should be taken in doses of 2.5 mL of syrup 3 times a day. In children over 5 years 5 mL of syrup, 3 times a day.
For the aerosol in adults and children over 5 years of age, a single-dose vial to be nebulised, 2 times a day. In children aged between 2 and 5 years, half a container 1-2 times a day.
For nebulizing suspensions in children from 5 years of age and adults 2-3 mL, 1-2 times a day. In children aged between two and five years, 2 mL 1-2 times a day.
For patients suffering from renal insufficiency and patients suffering from hepatic insufficiency , the doctor’s opinion should be sought before starting the administration as there could be an accumulation of ambroxol metabolites inside the liver.
Overdose
Studies have been carried out for the intake of Fluibron® in the event of an overdose, but no symptoms of an overdose are currently known. In the event of accidental intake of high doses of Fluibron®, contact your doctor or the nearest hospital.
Can it be taken during pregnancy?
Can Fluibron® be taken during pregnancy? And while breastfeeding? The drug should not be taken during pregnancy or breastfeeding without first consulting your doctor. This active ingredient is contraindicated during the first three months of pregnancy.
It is advisable not to take the drug while breastfeeding even if no effects on the infant are currently known. Take the medicine only on the advice of your doctor and only if necessary. Do not take any drug or supplement during pregnancy or breastfeeding without first consulting your doctor.
Contraindications
The use of Fluibron® is contraindicated in the case of overt hypersensitivity to ambroxol hydrochloride or to any of the excipients present in the drug. The excipients present in the drug are:
- For the tablets: microcrystalline cellulose, lactose monohydrate, sodium starch carboxymethyl (type A), magnesium stearate, colloidal anhydrous silica;
- For the syrup: glycerol, citric acid monohydrate, non-crystallisable sorbitol solution 70%, sodium saccharin, propyl p-hydroxybenzoate, methyl p-hydroxybenzoate, strawberry flavour, corrective flavour, purified water, silicone suspension;
- For the granules for suspension: mannitol, orange flavor, sorbitol, citric acid monohydrate, gum arabic, saccharin sodium, glycine, colloidal anhydrous silica, yellow orange S (E 110);
- For the aerosol: sodium chloride, water for injections;
- For the oral suspension: methyl p-hydroxybenzoate, propyl p-hydroxybenzoate, sodium chloride, purified water.
The drug is contraindicated in hypersensitive patients and in those with severe liver or kidney disease. The product is contraindicated in children under 2 years of age, this is because mucolytics could cause obstruction of the respiratory tract or bronchi.
Fluibron tablets® contains lactose and sugars, if there are intolerances to some sugars, seek medical advice first. In patients with lactose intolerance, the drug may cause some discomfort.
Interactions
There are currently no known drug interactions with other medicines. However, it is advisable to consult your doctor and warn him if you are taking, will need to take, or have recently taken any other medicine during therapy with Fluibron® .
Side effects
Like all pharmaceutical products, this medicine too can cause side effects even if not everyone gets them. The administration of Fluibron® should be stopped immediately if hypersensitivity reactions occur.
Contact your doctor or the nearest hospital if any of the following conditions appear such as:
- Itching;
- Urticaria;
- Swelling of the face, eyes, throat or lips;
- Difficulty breathing
- Skin rash.
Common side effects which may affect up to 1 in 10 people: nausea, decreased sense of taste or alteration, numbness of the mouth and/or pharynx.
Uncommon side effects which may affect up to 1 in 100 people: vomiting, indigestion, diarrhoea, abdominal pain, dry mouth.
Rare side effects , which may affect up to 1 in 1,000 people): headache.
Undesirable effects with unknown frequency : dry throat, obstruction of the airways.
It is advisable to report undesirable effects not listed in the leaflet. If the person experiences any side effects not listed in the package leaflet of the medicine, they should contact their doctor or pharmacist.
The doctor or pharmacist will help the patient report hitherto unknown side effects. To report undesirable effects, you can use the national reporting system by clicking on the address www.agenziafarmaco.gov.it.
Undesirable effects should be reported to help provide the National Health System with further information on the characteristics and safety of this product.
She defines herself as curious by nature. In 2006 she graduated with honors in Biotechnology at the Sapienza University of Rome. Between 2005 and 2009, she carried out a university internship and research activity in the field of tumor immunotherapy. She is a co-author of three scientific publications. Since 2007 you have associated your passion for science with that for the web, starting the management of the FitnessEquilibrium.com project.